Nestlé Discontinues Palforzia Peanut Allergy Treatment | Update 2024

Nestlé has divested its peanut allergy treatment, Palforzia, to Stallergenes Greer, a biopharmaceutical company specializing in allergy diagnosis and treatment. The transaction, finalized immediately upon signing, marks a swift exit for the food and beverage giant from a market it entered with significant investment less than three years ago. Nestlé originally acquired Palforzia through its $2 billion-plus acquisition of Aimmune Therapeutics in 2020, anticipating blockbuster sales for the first and only FDA-approved oral immunotherapy for peanut allergy. Palforzia is designed to reduce the risk of allergic reactions to peanuts in children aged one to seventeen. However, the drug reportedly underperformed expectations, prompting Nestlé’s decision to sell the business. Stallergenes Greer’s acquisition includes the Palforzia product and associated intellectual property. The company has a focused portfolio in allergy, making it a logical acquirer for the specialized treatment. The sale concludes Nestlé’s foray into the peanut allergy therapeutics market, a venture that began with high hopes but ultimately failed to deliver the anticipated financial returns. The company has not publicly disclosed the financial terms of the divestiture to Stallergenes Greer. Palforzia’s development and approval were hailed as a breakthrough for individuals and families managing peanut allergies. The treatment works by gradually introducing patients to increasing doses of peanut protein, aiming to desensitize them and reduce the severity of reactions to accidental exposure. The product’s journey involved real patients and caregivers, compensated for their participation in studies and testimonials, alongside healthcare professionals involved in its treatment.